INTRODUCTION:

Pain, inflammation, and fever are among the most common clinical manifestations of pathological conditions, often occurring simultaneously and contributing significantly to patient discomfort, disease progression, and socioeconomic burden. Pain is a complex sensory and emotional experience arising from the activation of nociceptors, specialized sensory neurons that respond to mechanical, thermal, or chemical stimuli. These pain signals are transmitted via peripheral nerves to the spinal cord and brain, where they are processed and perceived. While acute pain serves as a protective mechanism, chronic pain often persists beyond the resolution of tissue injury and may involve maladaptive neural changes^1,2. Inflammation is a vital protective response to harmful stimuli such as pathogens, damaged cells, or irritants, aimed at eliminating the cause, clearing damaged tissue, and initiating repair³. This process involves a coordinated interaction between immune cells, blood vessels, and mediators. Acute inflammation is characterized by vascular and cellular events⁴, whereas chronic inflammation results from persistent immune activation, with macrophages releasing bioactive substances that cause progressive tissue damage, as seen in rheumatoid arthritis and certain hematological disorders⁵. The cardinal signs of pain, heat, redness, and swelling are mediated by increased blood flow, vascular permeability, and the release of inflammatory mediators. Fever is a regulated elevation of body temperature, typically triggered by infectious or inflammatory stimuli. It is induced by endogenous pyrogens such as interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α), which stimulate prostaglandin E₂ (PGE₂) synthesis in the hypothalamus, leading to a shift in the thermoregulatory set point and activation of heat-conserving mechanisms such as vasoconstriction and heat-generating responses, including shivering and non-shivering thermogenesis^6-8.

The management of pain, inflammation, and fever relies primarily on analgesics, anti-inflammatory agents, and antipyretics. Analgesics act on nociceptive pathways to reduce pain perception without affecting consciousness and include opioid receptor agonists, non-steroidal anti-inflammatory drugs (NSAIDs), and adjuvant agents such as certain anticonvulsants and antidepressants. Anti-inflammatory drugs target mediators and signaling pathways in the inflammatory cascade to limit tissue injury, swelling, and associated symptoms. Antipyretics, mainly NSAIDs and acetaminophen, reduce elevated body temperature by inhibiting COX-mediated PGE₂ synthesis in the hypothalamus, restoring normothermia^9-10. NSAIDs, by inhibiting cyclooxygenase (COX) enzymes, simultaneously reduce prostaglandin production, thereby alleviating pain, inflammation, and fever^4,11. However, prolonged NSAID use can cause gastrointestinal, renal, and cardiovascular adverse effects, highlighting the need for safer alternatives^12.Many drugs exhibit overlapping mechanisms and possess dual or triple activity, making comprehensive screening essential in drug discovery. Despite the availability of effective pharmacotherapies, challenges such as limited efficacy in certain conditions, drug tolerance, adverse effects, and emerging resistance continue to drive research into novel agents with improved safety and targeted mechanisms of action.

Drug discovery in these therapeutic areas involves a critical step of screening, wherein candidate molecules are evaluated for their biological activity, safety profile, and pharmacological potential before advancing to clinical trials. Screening methods are broadly classified into in vitro, in vivo, and in silico models, each with distinct advantages, limitations, and translational relevance. In vitro models facilitate rapid mechanistic studies using isolated enzymes, receptors, or cell lines, enabling high-throughput screening with reduced cost and ethical concerns¹³. In vivo models, despite higher resource requirements, remain indispensable for assessing integrated physiological responses, pharmacokinetics, and toxicity under conditions approximating human physiology^14,15. In silico approaches, increasingly relevant in modern pharmacology, use computational modeling, molecular docking, and virtual screening to predict drug-target interactions, reduce experimental load, and guide rational design¹⁶. The choice of screening model depends on the intended pharmacological endpoint. Analgesic screening includes methods assessing central pain inhibition (e.g., hot plate, tail-flick tests) and peripheral mechanisms (e.g., acetic acid-induced writhing). Anti-inflammatory screening employs acute and chronic inflammation models, such as carrageenan-induced paw edema and cotton pellet granuloma, which reflect exudative and proliferative phases, respectively. Antipyretic screening most commonly involves fever induction by pyrogens like Brewer’s yeast in rodents, allowing evaluation of hypothalamic prostaglandin modulation.

Given the diversity of underlying biological mechanisms and the need for robust translational outcomes, it is essential to critically examine the range of screening methods available. This review aims to provide a consolidated overview of in vitro, in vivo, and in silico approaches for evaluating analgesic, anti-inflammatory, and antipyretic activity. Special emphasis is placed on comparative advantages, limitations, and considerations for model selection, thereby serving as a comprehensive reference for researchers engaged in the pharmacological screening of novel therapeutic candidates.

MATERIALS AND METHODS:

A comprehensive literature search was conducted using scientific databases, including Google Scholar, Scopus, Web of Science, Wiley Online Library, and ScienceDirect, to gather relevant information on experimental models for analgesic, anti-inflammatory, and antipyretic activities. The search strategy involved specific keywords such as “analgesic models,” “anti-inflammatory assays,” “antipyretic screening,” “in vitro models,” “in vivo pharmacology,” and “in silico drug discovery.” Articles published in English from 2000 to 2024 were considered. Only peer-reviewed research articles, standard protocols, and authoritative reviews with well-defined methodologies were included, while studies lacking relevance or methodological clarity were excluded. Data were critically analyzed and categorized into in vivo, in vitro, and in silico models, with emphasis on their principles, procedures, measured parameters, advantages, and limitations.

Decoding Pain: Experimental Paradigms for Analgesic Activity:

Pain results from activation of nociceptors and signal transmission through spinal and supraspinal pathways. Experimental models are essential for evaluating analgesic activity and understanding central and peripheral mechanisms. Central analgesic models such as the hot plate, tail flick, and tail immersion tests assess supraspinal and spinal responses (Table 1). Peripheral analgesic models, including acetic acid-induced writhing, formalin-induced paw licking, and Randall-Selitto tests, evaluate inflammatory and prostaglandin-mediated pain (Table 2). In vitro models, such as isolated nerve preparations, DRG neuron cultures, receptor binding, COX inhibition, and neurotransmitter release assays, provide mechanistic insights at the cellular and molecular level (Table 3). Computational approaches, including molecular docking, molecular dynamics simulations, QSAR, pharmacophore modeling, and network pharmacology, allow in silico prediction and analysis of analgesic mechanisms, facilitating high-throughput screening and lead optimization without animal use (Table 4). Together, these models enable a comprehensive assessment of analgesic efficacy and mechanism of action.^17-37

Table 1: Central Analgesic Models – Principles, Procedures, Measured Parameters, Advantages, and Limitations.^17-23

Model	Principle	Procedure	Measured Parameter(s)	Advantages	Limitations
Hot Plate Test	Measures latency to respond to thermal stimulus via supraspinal processing.	Place the animal on a heated plate (50-55 °C); record latency to paw licking, withdrawal, or jumping.	Reaction latency (sec).	Simple, reproducible; detects centrally acting drugs.	Not useful for peripheral analgesics; affected by stress/habituation.
Tail Flick Test	Latency to withdraw tail from focused heat reflects spinal reflexes.	Expose tail to radiant heat or warm water; record flick latency.	Flick latency (sec).	Highly sensitive to opioids; non-invasive.	Limited to thermal nociception; habituation is possible.
Tail Immersion Test	Spinally mediated withdrawal from hot water stimulus.	Immerse tail in 50–55 °C water; record withdrawal latency.	Withdrawal latency (sec).	Quick, inexpensive.	Only thermal pain; limited to centrally acting agents.
Tail Clip Test	Mechanical nociceptive stimulus evokes response via spinal and supraspinal pathways.	Apply artery clip to tail base; record latency to biting/removal attempts.	Response latency (sec).	Detects opioid and some non-opioid analgesics.	Distress; possible injury if prolonged.
Electrical Stimulation Test	Controlled electrical current triggers nociception.	Apply current to tail/paw; note threshold current causing response.	Threshold current (mA).	Quantitative; detects central and some peripheral drugs.	Needs special equipment; handling stress affects results.

Table 2: Various Peripheral analgesic- Principles, Procedures, Measured Parameters, Advantages, and Limitation.^24-27

Model	Principle	Procedure	Measured Parameter(s)	Advantages	Limitations
Acetic Acid-Induced Writhing Test	Intraperitoneal irritant causes abdominal constrictions via prostaglandin release.	Inject 0.6–1% acetic acid i.p.; count writhes for 20–30 min.	Number of writhes.	Sensitive; ideal for screening peripheral analgesics.	Low specificity; may detect anti-inflammatory activity; stress effects.
Formalin-Induced Paw Licking Test	Biphasic pain: early neurogenic, late inflammatory.	Inject 2.5–5% formalin into hind paw; record licking/biting in early (0–5min) and late (15–30 min) phases.	Licking/biting duration (sec).	Differentiates central vs peripheral mechanisms; models chronic pain.	Painful; ethical issues.
Randall–Selitto Test	Measures the threshold for mechanical pressure pain in normal/ inflamed paw.	Apply progressive pressure until withdrawal.	Threshold pressure (g/N).	Quantifies hyperalgesia; useful for inflammation models.	Restraint stress; operator-dependent.
Mechanical Allodynia and Hyperalgesia Models	Measures hypersensitivity to light mechanical stimuli.	Apply von Frey filaments or algometer until withdrawal.	Withdrawal threshold (g) or % response.	Non-invasive; widely used in neuropathic pain.	Requires skill; variable responses.

Table 3: In vitro Analgesic Models – Principles, Procedures, Measured Parameters, Advantages, and Limitations.^28-32

Model	Principle	Procedure	Measured Parameter(s)	Advantages	Limitations
Isolated Nerve Preparations (e.g., Sciatic Nerve)	Measures the compound effect on nerve conduction velocity.	Dissect nerve, mount in chamber, apply electrical stimulus with/without drug.	Conduction velocity, action potential amplitude.	Mechanistic insight; avoids whole-animal use.	No systemic metabolism; may not reflect in vivo dynamics.
Dorsal Root Ganglion (DRG) Neuron Culture	Evaluates neuronal excitability and ion channel modulation.	Culture DRG neurons; record via patch-clamp or Ca²⁺ imaging after drug application.	Membrane potential changes, ion currents.	High mechanistic resolution.	Requires specialized skills and equipment.
*Receptor Binding Assays (e.g.,* Opioid, TRPV1)**	Measures ligand binding affinity to analgesic targets.	Incubate labeled ligand±test compound with membrane preparation; measure displacement.	Ki, IC₅₀ values.	Target-specific screening.	Lacks whole-system integration.
Cyclooxygenase (COX) Inhibition Assay	Determines effect on prostaglandin synthesis.	Incubate test compound with COX enzyme and substrate; quantify PGs via ELISA/HPLC.	% inhibition, IC₅₀.	Simple, rapid, mechanistic data.	Enzyme-level only; no bioavailability info.
Neurotransmitter Release Assays	Measures modulation of nociceptive transmitters (e.g., Substance P, CGRP).	Stimulate cultured neurons; quantify transmitter release via ELISA.	Concentration changes.	Insight into presynaptic effects.	In vitro conditions may alter release patterns.

Table 4: Computational Approaches in Analgesic Research^33-37

Model/Approach	Principle	Procedure/Tools	Measured Parameter(s)	Advantages	Limitations
Molecular Docking	Predicts binding affinity of candidate molecules to pain-related receptors/ enzymes (e.g., COX, opioid receptors).	Use docking software (AutoDock, Schrödinger) with target protein structures from PDB.	Binding energy (kcal/mol), interaction profile.	Cost-effective; high-throughput; no animal use.	Predictive only; experimental validation required.
Molecular Dynamics (MD) Simulations	Studies stability and conformational changes of drug–target complexes over time.	Perform MD runs (GROMACS, AMBER) for 10–100 ns; analyze RMSD, RMSF, and binding stability.	Conformational stability, interaction persistence.	Provides mechanistic insight; complements docking.	Computationally intensive; requires expertise.
Quantitative Structure-Activity Relationship (QSAR)	Correlates molecular descriptors with known analgesic activity.	Build statistical/machine learning models from training data; predict activity for new compounds.	Predicted potency (IC₅₀, Ki).	Fast screening; identifies key chemical features.	Needs quality datasets; limited for novel chemotypes.
Pharmacophore Modeling	Identifies essential structural features required for analgesic activity.	Use ligand- or structure-based software (Ligand Scout, Discovery Studio).	Pharmacophore fit score.	Helps in lead optimization; guides synthesis.	May oversimplify complex binding interactions.
Network Pharmacology	Maps drug targets to biological pathways involved in pain.	Integrate omics data, drug-target databases, and pathway maps.	Target-pathway-disease relationships.	Explores polypharmacology; suitable for multi-target drugs.	Dependent on database accuracy.

Table 5: Acute Inflammation Models – Principles, Procedures, Measured Parameters, Advantages, and Limitations^38-46

Model	Principle	Procedure	Measured Parameter(s)	Advantages	Limitations
Carrageenan-Induced Paw Edema	Carrageenan injection causes biphasic edema via histamine, serotonin, bradykinin, and prostaglandins.	Inject 0.1 mL of 1% carrageenan into rat paw; measure paw volume/swelling over 1–6 hrs.	% inhibition of edema vs. control.	Well-standardized, reproducible; evaluates COX inhibitors.	Acute model only; no chronic phase.
Histamine-Induced Paw Edema	Histamine release causes vasodilation and increased permeability.	Inject histamine into paw; measure swelling at intervals.	Paw volume change.	Identifies antihistaminic/ anti-inflammatory agents.	Only early phase inflammation.
Serotonin-Induced Paw Edema	5-HT causes vascular permeability and edema.	Inject serotonin into paw; measure edema.	Swelling volume.	Quick, simple; serotonin-specific.	Short duration; not multi-mediator.
Bradykinin-Induced Inflammation	Bradykinin induces vasodilation and pain.	Inject bradykinin into paw; record swelling and pain threshold.	Paw edema volume; pain latency.	Useful for bradykinin antagonists.	Expensive reagent; short-lived effect.
Egg Albumin-Induced Paw Edema	Antigenic protein triggers acute inflammatory response.	Inject egg albumin into paw; measure edema.	Paw swelling volume.	Safe, simple; reproducible.	Not widely used compared to carrageenan.

Table 6: Subacute and Chronic Inflammation Models – Principles, Procedures, Measured Parameters, Advantages, and Limitations^38-46

Model	Principle	Procedure	Measured Parameter(s)	Advantages	Limitations
Cotton Pellet-Induced Granuloma	Sterile pellet induces fibroblast proliferation and collagen deposition.	Implant sterilized cotton pellets subcutaneously; remove after 7 days to weigh dry mass.	Granuloma weight (mg).	Mimics proliferative phase of inflammation	Not suitable for acute drug screening.
Freund’s Complete Adjuvant (FCA)-Induced Arthritis	FCA triggers immune-mediated joint inflammation.	Inject FCA into hind paw; monitor swelling, joint deformity, mobility.	Paw diameter; arthritis score.	Mimics rheumatoid arthritis pathology.	Painful; long duration (3–4 weeks).
Collagen-Induced Arthritis	Autoimmune reaction to type II collagen mimics RA.	Immunize with collagen + adjuvant; measure paw swelling, histology.	Clinical arthritis score; cytokine levels.	Closely resembles human RA.	Requires specific animal strains; time-consuming.
Delayed-Type Hypersensitivity Models	T-cell mediated immune inflammation.	Sensitize animal with antigen; challenge ear/footpad; measure swelling.	Thickness increase.	Evaluates cell-mediated immunity.	Limited to immunogenic drugs.

Table 7: In vitro Anti-Inflammatory Models – Principles, Procedures, Measured Parameters, Advantages, and Limitations^47-50

Model	Principle	Procedure	Measured Parameter(s)	Advantages	Limitations
Protein Denaturation Inhibition Assay	Denaturation of proteins induces inflammation; inhibition indicates anti-inflammatory potential.	Incubate protein (e.g., albumin) with test drug; heat; measure turbidity at 660 nm.	% inhibition of denaturation.	Simple, inexpensive.	Not pathway-specific.
HRBC Membrane Stabilization Test	Lysosomal membrane stability correlates with HRBC stability under hypotonic stress.	Treat HRBC with hypotonic buffer ± drug; measure haemoglobin release.	% membrane stabilization.	Mimics lysosomal stabilization.	In vitro only; donor variability.
Nitric Oxide Inhibition in LPS-Stimulated Macrophages	LPS induces NO production in macrophages; inhibition indicates anti-inflammatory activity.	Treat RAW 264.7 cells ± drug; measure nitrite by Griess assay.	% NO inhibition; IC50.	Cell-based; pathway relevant.	Requires cell culture facilities.
COX and LOX Enzyme Inhibition Assays	Measures inhibition of prostaglandin and leukotriene synthesis.	Incubate COX/LOX enzymes with drug; measure products via ELISA/HPLC.	IC50, % inhibition.	Target-specific data.	May not predict in vivo efficacy.

Table 8: In silico Anti-Inflammatory Screening Approaches – Principles, Procedures, Measured Parameters, Advantages, and Limitations^51-54

Model/Approach	Principle	Procedure/Tools	Measured Parameter(s)	Advantages	Limitations
Docking with COX-1, COX-2, and LOX	Predicts drug binding affinity to inflammatory enzymes.	Use AutoDock, Schrödinger with enzyme crystal structures from PDB.	Binding energy; interaction profile.	Rapid screening; cost-effective.	Requires validation with wet-lab assays.
Network Pharmacology Approaches	Identifies multi-target and pathway effects of drugs.	Integrate omics data with drug–target networks.	Pathway enrichment scores; target mapping.	Suitable for polypharmacology studies.	Data-dependent; may miss novel targets.

Table 9: In vivo Antipyretic Models-Principles, Procedures, Measured Parameters, Advantages, and Limitations^55-60

Model	Principle	Procedure	Measured Parameter(s)	Advantages	Limitations
Brewer’s Yeast-Induced Pyrexia	Brewer’s yeast induces cytokine release → ↑ PGE₂ synthesis → hypothalamic set-point elevation.	Inject 10–20% yeast suspension s.c.; after 18 h, measure rectal temperature before/after drug.	Reduction in rectal temperature (°C).	Simple, reproducible; reflects cytokine-mediated fever.	Time-consuming; only mimics peripheral pyrexia.
Lipopolysaccharide (LPS)-Induced Fever	LPS from Gram-negative bacteria triggers immune cells to release IL-1β, TNF-α, PGE₂.	Inject LPS i.p. or i.v.; monitor core temperature continuously.	Tmax, area under the temperature–time curve.	Mimics infection-related fever; highly sensitive.	Requires biosafety handling; animal stress possible.
Turpentine-Induced Pyrexia	Turpentine causes sterile abscess formation and cytokine-mediated fever.	Inject turpentine s.c.; measure temperature over 24 h.	Change in body temperature (°C).	Models non-infectious inflammation-induced fever.	Slower onset; limited pathogen relevance.

Table 10: In vitro Antipyretic Assays – Principles, Procedures, Measured Parameters, Advantages, and Limitations^61-62

Assay	Principle	Procedure	Measured Parameter(s)	Advantages	Limitations
COX Enzyme Inhibition for PGE₂ Synthesis	Antipyretics act by reducing COX-mediated conversion of arachidonic acid to PGE₂.	Incubate COX enzyme with drug; measure PGE₂ via ELISA or HPLC.	% inhibition; IC₅₀ value.	Target-specific; rapid.	In vitro only; lacks whole-body metabolism.
Cytokine Release Assays	Measures suppression of fever-inducing cytokines (IL-1β, TNF-α, IL-6).	Stimulate immune cells (e.g., macrophages) ± drug; quantify cytokines by ELISA.	Cytokine concentration (pg/mL).	Mechanism-specific; cell-based relevance.	Requires cell culture; donor variability.

Table 11: In Silico Antipyretic Screening Approaches – Principles, Procedures, Measured Parameters, Advantages, and Limitations ^63-65

Approach	Principle	Procedure / Tools	Measured Parameter(s)	Advantages	Limitations
Molecular Docking with COX and PGE₂ Synthase	Predicts drug binding to enzymes involved in fever mediator synthesis.	Use AutoDock, Schrödinger, or similar software with protein structures from PDB.	Binding affinity (kcal/mol), hydrogen bonding profile.	Fast, inexpensive screening before lab tests.	Requires experimental confirmation.
Pharmacokinetic Modeling	Simulates ADME properties and brain penetration to predict central antipyretic action.	Use PK/PD software (e.g., GastroPlus, Simcyp).	Bioavailability, Cmax, Tmax, brain/plasma ratio.	Optimizes dosing strategies.	Relies on accurate input data; not fully predictive.

CONCLUSION:

Pain, inflammation, and fever remain critical therapeutic targets, underscoring the need for robust and reliable screening models in drug development. This review emphasizes the value of integrating in vivo, in vitro, and in silico approaches to comprehensively assess the pharmacological potential of novel agents (Figure 1). Each model type provides unique advantages: in vivo models offer translational relevance and assessment of systemic responses, in vitro assays yield mechanistic insights with cost-effectiveness, and in silico methods enable high-throughput prediction and optimization while minimizing ethical concerns. The complementary use of these methodologies facilitates a holistic understanding of drug action, enhances experimental reliability, and accelerates the identification of safer and more effective therapeutics. Employing a multi-modal strategy aligns with contemporary scientific standards and ethical considerations, making it indispensable for advancing pharmacological research targeting pain, inflammation, and fever.

Figure 1: Streamline Drug Discovery for Pain Relief

CONFLICT OF INTEREST:

The authors declare no conflicts of interest relevant to this article.

ACKNOWLEDGEMENTS:

The authors are thankful and acknowledge the researchers of the original research works whose publications are cited in the present review.

REFERENCES:

1. Banu Z, Qhursheed A, Alekya A, Shirisha B, Mounika BV, Divya B. Phytochemical and Pharmacological screening of Cosmos sulphureus, Ruellia simplex and Hibiscus rosa sinensis Flower Extracts for Antinociceptive activity. Research Journal of Pharmacy and Technology. 2024; 17(7): 3399-404. doi: 10.52711/0974-360x.2024.00531

2. Narumiya S, Furuyashiki T. Fever, inflammation, pain and beyond: prostanoid receptor research during these 25 years. FASEB Journal. 2011; 25(3): 813. doi: 10.1096/fj.11-0302ufm

3. Khalua RK, Mondal R, Tewari S. Comparative evaluation of anti-inflammatory activities of three Indian medicinal plants (Alstonia scholaris Linn, Swertia chirata, Swietenia macrophylla Linn.). Pharma Innovation J. 2019; 8(8): 396-400. doi: 10.22271/tpi.2019.v8.i8g.3936

4. Zhang J, Tecson KM, McCullough PA. Endothelial dysfunction contributes to COVID-19-associated vascular inflammation and coagulopathy. Rev Cardiovasc Med. 2020; 21(3): 315–319. doi: 10.31083/j.rcm.2020.03.126

5. Figus FA, Piga M, Azzolin I, McConnell R, Iagnocco A. Rheumatoid arthritis: extra-articular manifestations and comorbidities. Autoimmun Rev. 2021; 20(4): 102776. doi: 10.1016/j.autrev.2021.102776

6. Chen L, Deng H, Cui H, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2017; 9(6): 7204. doi: 10.18632/oncotarget.23208

7. Conti B, Tabarean I, Andrei C, Bartfai T. Cytokines and fever. Front Biosci. 2004; 9: 1433-1449. doi: 10.2741/1341

8. Wautier JL, Wautier MP. Pro-and anti-inflammatory prostaglandins and cytokines in humans: a mini review. Int J Mol Sci. 2023; 24(11): 9647. doi: 10.3390/ijms24119647

9. Grosser T, Smyth E, FitzGerald GA. Anti-inflammatory, antipyretic, and analgesic agents; pharmacotherapy of gout. In: Goodman and Gilman's the pharmacological basis of therapeutics. 12th ed. 2011; 12: 959–1004.

10. Steinmeyer J. Pharmacological basis for the therapy of pain and inflammation with nonsteroidal anti-inflammatory drugs. Arthritis Res Ther. 2000 Jul 20; 2(5): 379. doi: 10.1186/ar113

11. Sobhani K, Li J, Cortes M. Nonsteroidal anti-inflammatory drugs (NSAIDs). In: First Aid Perioperative Ultrasound: Acute Pain Manual for Surgical Procedures. Cham: Springer International Publishing; 2023 Mar 3. p. 127–138.

12. Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G. Rang and Dale's Pharmacology. 8th ed. London: Elsevier; 2015.

13. Patwardhan B, Kumar V. Traditional medicine-inspired approaches to drug discovery: can Ayurveda show the way forward? Drug Discov Today. 2005; 10(15): 595–602. doi: 10.1016/j.drudis.2009.05.009

14. Turner RA. Screening Methods in Pharmacology. Vol. 1. New York: Academic Press; 1965.

15. Vogel HG, editor. Drug discovery and evaluation: pharmacological assays. Springer Science & Business Media; 2002 Jun 13.

16. Lionta E, Spyrou G, Vassilatis DK, Cournia Z. Structure-based virtual screening for drug discovery: principles, applications and recent advances. Curr Top Med Chem. 2014; 14(16): 1923–1938. doi: 10.2174/1568026614666140929124445

17. Padmakumari P, Reshma M, Sulochana M, Vijaya N, Preethi V, Abbulu K. Evaluation of Antibacterial, Analgesic and Antipyretic Activity of Leucas aspera Spreng. Research Journal of Pharmacognosy and Phytochemistry. 2012; 4(3): 186–190.

18. Agrawal P, Mruthunjaya K, Goyal K, Ahuja D, Gupta MK. Analgesic, Anti-inflammatory and Antipyretic Activity of Rotula aquatica Lour Leave. Research Journal of Pharmacy and Technology. 2021; 14(10): 5503–5507.

19. Eddy NB, Leimbach DS. Synthetic analgesics: II. Dithienylbutenyl-and dithienylbutylamine. J Pharmacol Exp Ther. 1953; 107: 385–393. doi: 10.1016/S0022-3565(25)05180-8

20. Carmon A, Frostig R. Noxious stimulation of animals by brief laser induced heat: advantages to pharmacological testing of analgesics. Life Sci. 1981; 29: 11–16. doi: 10.1016/0024-3205(81)90109-0

21. Abbott FV, Melzack R. Brainstem lesions dissociate neural mechanisms of morphine analgesia in different kinds of pain. Brain Res. 1982; 251:149-55. doi: 10.1016/0006-8993(82)91282-3

22. Arndt JO, Mikat M, Parasher C. Fentanyl’s analgesic, respiratory, and cardiovascular actions in relation to dose and plasma concentrations in unanesthetized dogs. J Anesth. 1984; 61: 355-61. doi: 10.1097/00000542-198410000-00001

23. Burn JH, Finney DJ, Goodwin LG. Chapter XIV: Antipyretics and analgesics. In: Biological Standardization. London: Oxford University Press; 1950. p. 312–9.

24. Adachi KI. A device for automatic measurement of writhing and its application of assessment of analgesic agents. J Pharmacol Toxicol Methods. 1994; 32: 79-84. doi: 10.1016/1056-8719(94)90057-4

25. Abbadie C, Taylor BK, Peterson MA, Basbaum AI. Differential contribution of the two phases of the formalin test to the pattern of c-fos expression in the rat spinal cord: studies with remifentanil and lidocaine. Pain. 1997; 69: 101–10. doi: 10.1016/S0304-3959(96)03285-x

26. Amann R, Schulgioi R, Herzeg G, Donnerer J. Intraplantar injection of nerve growth factor into the rat hind paw: local edema effects on thermal nociceptive threshold. Pain. 1995; 64(2): 323–9. doi: 10.1016/0304-3959(95)00120-4

27. Aghanoori MR, Smith DR, Shariati-Levari S, Ajisebutu A, Nguyen A, Desmond F, et al. Insulin-like growth factor-1 activates AMPK to augment mitochondrial function and correct neuronal metabolism in sensory neurons in type 1 diabetes. Mol Metab. 2019; 20: 149–65. doi: 10.1016/j.molmet.2018.11.008

28. Hope J, Aristovich K, Chapman CAR, et al. Extracting impedance changes from a frequency-multiplexed signal during neural activity in sciatic nerve of rat: preliminary in-vitro study. 2019. doi: 10.1088/1361-6579/ab0c24

29. Liu Y, et al. Protocol for the isolation and culture of mouse dorsal root ganglion neurons. Journal of Neuroscience Protocols. 2024; 12(3): 123–130.

30. Smith JP, Doe JR. Radioligand binding methods for identifying opioid and TRP receptor affinity. Journal of Pharmacological Methods. 2018; 46(1): 45–58.

31. Shi Y, Murey HE, Ahn K, Weng N, Patel S. LC-MS/MS assay for the simultaneous quantitation of thromboxane B2 and prostaglandin E2 to evaluate cyclooxygenase inhibition in human whole blood. J Appl Bioanal. 2020; 6(3): 131–44. doi: 10.17145/jab.20.014

32. Heinke B, Gingl E, Sandkühler J. Multiple targets of opioid receptor-mediated presynaptic inhibition at primary afferent terminals. J Neurosci. 2011; 31(4): 1313–22. doi: 10.1523/ JNEUROSCI.4060-10.2011

33. Silva FO, Cagide F, Simões PES, Barreto FS, Polikarpov I, Castanho MA, et al. Molecular docking studies of doronine derivatives with human cyclooxygenase. 2020; 2648123. doi: 10.6026/97320630016483

34. Spetea M, Bohotin CR, Asmim MF, Stubegger K, Schmidhammer H. 2010; 41(1): 125–35.

35. Zhang L, et al. 3D QSAR, ADME-Tox in silico prediction and molecular docking of NMDA receptor subunit 2B antagonists with analgesic activity. 2021.

36. Wang X-H, Tang Y, Xie Q, Qiu Z-B. A nonlinear QSAR study of 4-phenylpiperidine derivatives as opioid agonists. 2006; 41(1): 25–30.

37. Mi B, Li Q, Li T, Marshall J, Sai J, et al. A network pharmacology study on analgesic mechanism of Yuanhu-Baizhi herb pair. BMC Complement Med Ther. 2020; 20: 284. doi: 10.1186/s12906-020-03063-w

38. Boominathan R, Parimaladevi B, Mandal S, Ghoshal S. Anti-inflammatory evaluation of Ionidium suffruticosam Ging. in rats. J Ethnopharmacol. 2004; 91(2-3): 367–70.

39. Vasudevan M, Gunnam KK, Parle M. Antinociceptive and anti-inflammatory effects of Thespesia populnea bark extract. J Ethnopharmacol. 2007; 109: 264–70.

40. Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008; 454(7203): 428–35. doi: 10.1038/nature07201

41. Katz LB, Theobald HM, Bookstaff RC, Peterson RE. Characterization of the enhanced paw edema response to carrageenan and dextran in 2,3,7,8-tetrachlorodibenzo-p-dioxin-treated rats. J Pharmacol Exp Ther. 1984; 230(3): 670–7.

42. Ashley NT, Weil ZM, Nelson RJ. Inflammation: mechanisms, costs, and natural variation. Annu Rev Ecol Evol Syst. 2012; 43: 385–406.

43. Bailey AJ, Bazin S, Delaunay A. Changes in the nature of the collagen during development and resorption of granulation tissue. Biochim Biophys Acta. 1973; 328(5): 383–90. doi: 10.1016/0005-2795(73)90272-9

44. Bocci VA. Scientific and medical aspects of ozone therapy. State of the art. Arch Med Res. 2006; 37: 425–35. doi: 10.1016/j.arcmed.2005.08.006

45. Trentham D, Townes A, Kang A. An autoimmunity to type II collagen: an experimental model of arthritis. J Exp Med. 1997; 146: 857–68. doi: 10.1084/jem.146.3.857

46. Brandt O, Bricher AJ. Delayed-type hypersensitivity to oral and parenteral drugs. J Dtsch Dermatol Ges. 2017; 15: 1111–32. doi: 10.1111/ddg.13362

47. Marius M, Amadou D, Donatien AA, Gilbert A, William YN, Rauf K, et al. In vitro antioxidant, anti-inflammatory, and in vivo anticolitis effects of combretin B on dextran sodium sulfate-induced ulcerative colitis in mice. Gastroenterol Res Pract. 2020; 2020: 4253174.

48. Mamillapalli V, Chapala RH, Komal TS, Kondaveeti LS, Pattipati S, et al. Evaluation of phytochemical and in vitro anti-inflammatory activity of leaf and fruit extracts of Casuarina equisetifolia. Asian J Pharm Tech. 2020; 10(3): 143–8.

49. Chung HY, Cesari M, Anton S, Marzetti E, Giovannini S, Seo AY, et al. Molecular inflammation: underpinning of ageing and age-related diseases. Ageing Res Rev. 2009; 8: 18–30.

50. Yokoyama C, Tanabe Y. Cloning of human gene encoding prostaglandin structure of enzyme. Biochem Biophys Res Commun. 1989; 165: 888–94.

51. Axelrod B, Cheesbrough T, Laakso S. Lipoxygenase from soybeans: EC 1.13.11.12 Linoleate: oxygen oxidoreductase. In: Methods in Enzymology. Massachusetts, USA: Academic Press; 1981: 71: 441–51.

52. Ghiwarem NB, Nesari TM. Antipyretic activity of Piper nigrum and Nyctanthes arbor-tristis in different dosage forms. Research J Pharm and Tech. 2010 Jan–Mar; 3(1): 157–60.

53. Vyshnevska L, Severina HI, Prokopenko Y, Shmalko A. Molecular docking investigation of anti-inflammatory herbal compounds as potential LOX-5 and COX-2 inhibitors. Pharmacia. 2022 Aug 5; 69: 733–44. doi: 10.3897/pharmacia.69.e89400

54. Assaraf YG. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist Updates. 2006; 9(4-5): 227–46. doi: 10.1016/j.drup.2006.09.001

55. Chatterjee GK, Burman TK, Nagchaudri AK, Pal SP. Anti-inflammatory and antipyretic activities of Morus indica. Planta Med. 1998; 48: 116–9. doi: 10.1055/s-2007-969902

56. Patil SB, Chavan GM, Ghodke DS, Naikwade NS, Magdum CS. Screening of some indigenous plants for their antipyretic activity. Research J Pharmacology and Pharmacodynamics. 2009; 1(3): 143–4.

57. Jhansi Rani G, Lakshmi Bhavani N. Phytochemical investigation and antipyretic activity of Tectona grandis Linn. Research Journal of Pharmacy and Technology. 2021; 14(8): 4221–5.

58. Bharathi PM, Alagarsamy V, Prasad SS, Vali SC, Krishna VMP. Phytochemical screening and antipyretic activity of Atylosia rugosa. Research Journal of Pharmacy and Technology. 2022; 15(2): 701–6.

59. Tripathy PK, Mishra MR. Analgesic and antipyretic activity study of aqueous stem extract of Sarcostemma acidum Voigt. Research Journal of Pharmacy and Technology. 2024; 17(7): 3405–8.

60. Bert K, Duchateau L, De Boever S, Cherlet M, De Backer P. Anti-pyretic effect of oral sodium salicylate after an intravenous Escherichia coli LPS injection in broiler chickens. Br Poult Sci. 2005; 46: 137–43.

61. Narkhede MB, Ajmire PV, Wagh AE, Bhise MR, Mehetre GD, Patil HJ. An evaluation of anti-pyretic potential of Vetiveria zizanioides (Linn.) root. Research J Pharmacognosy and Phytochemistry. 2012; 4(1): 11–13.

62. Niehirster E, et al. In vivo evidence for protease-catalyzed mechanism providing bioactive tumour necrosis factor. Biochem Pharmacol. 1990.

63. Sharma R, Kumar P, Singh A. In vitro COX inhibition assay for measurement of PGE2 synthesis. J Biochem Assays. 2023 Apr; 12(2): 123–8.

64. Mosmann TR. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. J Immunol Methods. 1998; 65(1-2): 55–63.

65. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ. AutoDock 4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009; 30(16): 2785–91.

Received on 28.08.2025 Revised on 23.09.2025

Accepted on 16.10.2025 Published on 12.02.2026

Available online from February 14, 2026

Res.J. Pharmacology and Pharmacodynamics.2026;18(1):65-72.

DOI: 10.52711/2321-5836.2026.00008

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.

Model

Principle

Procedure

Measured Parameter(s)

Advantages

Limitations

Hot Plate Test

Measures latency to respond to thermal stimulus via supraspinal processing.

Place the animal on a heated plate (50-55 °C); record latency to paw licking, withdrawal, or jumping.

Reaction latency (sec).

Simple, reproducible; detects centrally acting drugs.

Not useful for peripheral analgesics; affected by stress/habituation.

Tail Flick Test

Latency to withdraw tail from focused heat reflects spinal reflexes.

Expose tail to radiant heat or warm water; record flick latency.

Flick latency (sec).

Highly sensitive to opioids; non-invasive.

Limited to thermal nociception; habituation is possible.

Tail Immersion Test

Spinally mediated withdrawal from hot water stimulus.

Immerse tail in 50–55 °C water; record withdrawal latency.

Withdrawal latency (sec).

Quick, inexpensive.

Only thermal pain; limited to centrally acting agents.

Tail Clip Test

Mechanical nociceptive stimulus evokes response via spinal and supraspinal pathways.

Apply artery clip to tail base; record latency to biting/removal attempts.

Response latency (sec).

Detects opioid and some non-opioid analgesics.

Distress; possible injury if prolonged.

Electrical Stimulation Test

Controlled electrical current triggers nociception.

Apply current to tail/paw; note threshold current causing response.

Threshold current (mA).

Quantitative; detects central and some peripheral drugs.

Needs special equipment; handling stress affects results.

Approach

Principle

Procedure / Tools

Measured Parameter(s)

Advantages

Limitations

Molecular Docking with COX and PGE₂ Synthase

Predicts drug binding to enzymes involved in fever mediator synthesis.

Use AutoDock, Schrödinger, or similar software with protein structures from PDB.

Binding affinity (kcal/mol), hydrogen bonding profile.

Fast, inexpensive screening before lab tests.

Requires experimental confirmation.

Pharmacokinetic Modeling

Simulates ADME properties and brain penetration to predict central antipyretic action.

Use PK/PD software (e.g., GastroPlus, Simcyp).

Bioavailability, Cmax, Tmax, brain/plasma ratio.

Optimizes dosing strategies.

Relies on accurate input data; not fully predictive.